Interstitial lung diseases often are accompanied by histopathologic evidence of alveolar type 2 cell alterations. In the alveolar milieu, the surfactant-specific protein A (SP-A) is a secretory product of alveolar type 2 cells.
Interstitial lung diseases often are accompanied by histopathologic evidence of alveolar type 2 cell alterations. In the alveolar milieu, the surfactant-specific protein A (SP-A) is a secretory product of alveolar type 2 cells.
Therefore, we measured SP-A levels in bronchoalveolar lavage (BAL) fluids from patients with untreated sarcoidosis (n=35) and hypersensitivity pneumonitis (HP [n=10] ) and compared the results with those from 21 healthy control subjects. In sarcoidosis patients, SP-A was markedly higher than in control subjects with a mean of 8.0 ,g/ml of recovered BAL fluid + 0.7 SEM (p<0.0001 compared with control subjects). In HP, SP-A values were comparable with those in sarcoidosis with a mean of 9.0 ,tg/ml + 1.7 SEM. Mean SP-A in the control group was 4.0 ,g/ml + 0.3 SEM. These results sug- In the alveolar milieu, surfactant specific proteins are synthesized and secreted by alveolar type 2 cells and represent important constituents of the alveolar surfactant complex. In concert with surfactant phospholipids, they support the reduction of the alveolar surface tension down to levels that are required for alveolar stability during the ventilatory cycle and thus for an adequate alveolar gas exchange.
Surfactant specific protein A (SP-A) is the major surfactant protein in regard to relative abundance in the surfactant complex and has been intensively studied in recent years.1 In the alveoli, it is secreted by alveolar type 2 10 subjects were lifetime nonsmokers, and 11 were current cigarette smokers.
Techniques
Bronchoscopy and Bronchoalveolar Lavage: All investigated subjects underwent fiberoptic bronchoscopy. After premedication with atropine and codeine and local anesthesia with 2 percent lidocaine, the bronchoscope was wedged in a segment or subsegment of the middle lobe or lingula, and BAL was carried out with 100 ml of 0.9 percent saline solution (5 aliquots of 20 ml each). The mean recovery did not significantly differ among groups (Table 1) . Recovered BAL fluids were strained through gauze, and an aliquot was submitted for cytologic examination. The remaining fluid was centrifuged at 500 g for 10 mins to remove cells and debris. The cell-free supernatant was stored at -28°C for further analysis.
Analysis of Lavage Cells: The lavage fluid was centrifuged at 500 g, and the cell pellet was resuspended. Cytologic preparations were stained with May-Griinwald-Giemsa stain, and differential cell counts were performed on 600 cells. Lymphocyte subsets were analyzed by a peroxidase-antiperoxidase assay performed on The mean SP-A in the BAL fluids of this group (n=35) was 8.0±0.7 (SEM) ,ug/ml, with a range of 2.4 to 17.4 ,ug/ml (p<0.0001, compared with control subjects [Fig 1] ). The mean protein content of the fluids was 250 ± 62 (SEM) ,ug/ml, with a range of 19 to 2,242 ,g/ml, and the mean lymphocyte percentage of recovered cells, 46 ± 2.7 (SEM) percent, with a range of 11 to 85 percent. The mean CD4/CD8 lymphocyte ratio (performed in 25 patients) was 6.07 ±0.87 (SEM), with a range of 0.8 to 18, as also shown in Table 1 . In patients with type I sarcoidosis (n=22), the mean SP-A was 8.3 ±0.7 (SEM) ,ug/ml, with a range of 3.3 to 15.6 jig/ml. In type II sarcoidosis (n=13), the mean SP-A was 7.6±1.3 (SEM)
,ug/ml, with a range of 2.4 to 17.4 ,g/ml.
Hypersensitivity Pneumonitis
The mean SP-A in this group (n= 10) was 9.0 ± 1.7 (SEM) ,ug/ml of BAL fluid, with a range of 3.0 to 19.1 ,ug/ml (p<0.0001, compared with control subjects [Fig 1] ). The mean protein content of the fluids was 401 ± 178 (SEM) Ag/ml, with a range of 39 to 1, 888 ,g/ml. The mean lymphocyte percentage of recovered cells was 67+4.1 (SEM) percent, with a range of 45 to 85 percent. The mean CD4/CD8 lymphocyte ratio (performed in 9 patients) was 1.1±0.2 (SEM), with a range of 0.3 to 2.6 (Table 1) .
Control Subjects
The mean SP-A in this group (n=21) was 4.0 ± 0.3 (SEM) ,ug/ml of BAL fluid, with a range of 2.0 to 6.3 ,ug/ml. The mean total protein content was 82 ± 16 (SEM) ,ug/ml, with a range of 28 The percentage of SP-A per total protein content of BAL fluids (SP-A/total protein ratio) was similar in all three groups: it was 6.8 ± 1 in control subjects, 5.3 ±0.7 in sarcoidosis patients, and 6.3 ±2.2 in HP patients. There was a positive and significant correlation between these two factors in HP patients (r-0.733; p=0.016), but not in sarcoidosis patients (r=0.056) or control subjects (r=0.146).
DISCUSSION
We found significantly elevated SP-A levels in BAL fluids of 35 patients with untreated types I and II sarcoidosis and in 10 patients with untreated HP as compared with healthy control subjects (Fig 1) . In a preliminary report by Ishii and coworkers,'19 SP-A levels also were raised in sarcoidosis patients, while van de Graaf et a120 found only a slight, but not significant increase of SP-A in 20 sarcoidosis patients with untreated disease. The differences between our results and those of van to 63 ,ug/ml). Thus, SP-A;measurements may prove useful to exclude this disorder in the differential diagnosis of interstitial lung disease. SP-A levels similar to those observed in sarcoidosis or HP patients in our present study also have been reported in AIDSrelated pneumonia.33 Only one report has hitherto been published29 in which SP-A was determined in BAL fluids from 28 patients with idiopathic pulmonary fibrosis. The SP-A was found to be significantly lower than in normal control subjects. These findings may imply that idiopathic pulmonary fibrosis could be characterized by reduced BAL SP-A levels compared with other interstitial lung diseases. Certainly, further studies including higher patient numbers are needed to clarify this aspect. The SP-A levels measured in our control subjects were in general agreement with the results obtained by other groups using different BAL procedures and various other enzyme-linked immunosorbent assay techniques with different antibodies and standards. Our ten nonsmoking control subjects had a mean SP-A level of 3.4 ,g/ml; in smokers it was slightly higher (4.5 Aug/ml; with the difference not significant). Van In summary, our results suggest that SP-A levels in BAL fluids are not specific or diagnostic for sarcoidosis or HP. Elevated SP-A levels in these diseases, however, may reflect acute alveolar inflammation with reactive increase of the secretory activity of type 2 cells or probably of lesser importance, Clara cells, or both. It is tempting to speculate that SP-A levels could prove useful as an unspecific marker of disease activity or severity in acute interstitial lung disease like sarcoidosis or HP. This cQuld be clinically useful, since pulmonary medicine is still lacking a reliable marker of disease activity to calculate the risk of impending and potentially irreversible lung damage prior to the deterioration of lung function factors. Furthermore, SP-A measurement could prove helpful in the differential diagnosis of interstitial lung diseases including idiopathic pulmonary fibrosis and alveolar proteinosis.
